Expression, purification and crystallization of CTB-MPR, a candidate mucosal vaccine component against HIV-1

Lee, H.-H.; Cherni, I.; Yu, H.; Fromme, R.; Doran, J.D.; Grotjohann, I.; Mittman, M.; Basu, S.; Deb, A.; Dörner, K.; Aquila, A.; Barty, A.; Boutet, S.; Chapman, H.N.; Doak, R.B.; Hunter, M.S.; James, D.; Kirian, R.A.; Kupitz, C.; Lawrence, R.M.; Liu, H.; Nass, K.; Schlichting, I.; Schmidt, K.E.; Seibert, M.M.; Shoeman, R.L.; Spence, J.C.H.; Stellato, F.; Weierstall, U.; Williams, G.J.; Yoon, C.; Wang, D.; Zatsepin, N.A.; Hogue, B.G.; Matoba, N.; Fromme, P.; Mor, T.S.

doi:10.1107/S2052252514014900

Figure 5
CTBMPR exists in several metastable oligomeric forms. Affinity-purified CTBMPR was resolved by SEC–HPLC, yielding three major peaks probably corresponding to pentamers (fraction 8) and monomers (fraction 16). Fractions 21 and 23 did not contain appreciable amounts of protein and are likely to contain high concentrations of imidazole. The shoulder at the right of the pentamer peak (fraction 11) may represent the less stable intermediates tetramers and dimers. These fractions (numbered in red), alongside the original sample and a precipitate that formed in the original sample, were analyzed by SDS–PAGE followed by silver staining (inset).

IUCrJ

Volume 1| Part 5| August 2014| Pages 305-317

ISSN: 2052-2525

doi:10.1107/S2052252514014900

Open

access

Follow IUCrJ

Search IUCr Journals		doi		Advanced search
Author		volume	page